Depression treatment is often described as a process of finding the right drug at the right dose, but in hospital settings that decision can become a moving target. A new study published in Translational Psychiatry examines whether the frequency of therapeutic drug monitoring is linked to how long patients remain hospitalized while receiving precision care for depression. The research, led by Christian Hampf, Jürgen Deckert, Stefan Walther and colleagues, places a highly practical question at the center of personalized psychiatry: can measuring medication levels more systematically help clinicians manage complex depressive illness more efficiently?
Therapeutic drug monitoring, or TDM, involves measuring the concentration of a medicine—or its active metabolites—in a patient’s blood. The results can help doctors determine whether a drug is reaching an effective exposure, whether a patient is receiving too much, or whether an apparently ineffective treatment may actually be affected by poor absorption, rapid metabolism, drug interactions or inconsistent dosing. In psychiatric medicine, where treatment response can vary dramatically between individuals, blood-level data may offer information that cannot be obtained from symptoms alone.
The study focuses on inpatient precision depression care, a setting in which patients generally have severe, persistent or treatment-resistant symptoms and may require close clinical observation. These patients can differ substantially in genetics, metabolism, medical history and previous treatment exposure. A standard dose that produces therapeutic concentrations in one person may result in inadequate or excessive exposure in another. TDM is therefore potentially valuable, particularly when clinicians are changing medications, combining treatments or trying to understand why an expected improvement has not occurred.
The relationship with hospitalization is important because inpatient psychiatric care is resource-intensive and emotionally demanding for patients and families. The duration of a hospital stay reflects more than medication response alone: it may also depend on suicide risk, comorbid illness, social circumstances, psychotherapy, discharge planning and the availability of community support. Even so, medication optimization is often a central part of the admission. If laboratory monitoring helps clinicians reach a stable and effective regimen sooner, it could theoretically contribute to a shorter stay. Conversely, frequent testing may signal that a patient’s illness or medication regimen is unusually complicated, potentially identifying people who need longer care.
This distinction makes the study scientifically significant. A simple association between more frequent TDM and hospitalization duration would not prove that blood testing itself changes outcomes. Clinicians may order tests more often precisely because a patient is deteriorating, experiencing side effects or failing to respond. In that case, frequent monitoring would be a marker of clinical complexity rather than the cause of a prolonged admission. Establishing the direction of the relationship requires careful analysis of treatment histories, illness severity, medication changes and other factors that influence discharge.
The technical logic behind TDM depends on pharmacokinetics, the study of how the body absorbs, distributes, metabolizes and eliminates a drug. Many antidepressants are processed by liver enzymes, including members of the cytochrome P450 system. Genetic differences in these enzymes can make some individuals metabolize a medicine unusually quickly or slowly. Other medications, smoking, diet and physical illness can also alter drug concentrations. TDM provides a direct measurement of exposure, while pharmacogenetic testing estimates how a person may process a drug. Used together, the two approaches may help clinicians distinguish biological differences in metabolism from problems such as nonadherence or an inadequate treatment plan.
The research also arrives at a time when precision psychiatry is moving from a broad aspiration toward more measurable clinical strategies. In oncology, treatment decisions are often guided by molecular markers, while psychiatry has traditionally relied heavily on symptom scales, clinical experience and trial-and-error prescribing. Precision depression care seeks to combine those approaches with biological, pharmacological and clinical data. TDM is not a universal solution, and blood concentration does not perfectly predict therapeutic benefit. However, it can provide an additional layer of evidence when the relationship between dose and response is unclear.
For hospitals, the findings could have practical implications for how monitoring is organized. A highly selective approach might reserve testing for medicines with established concentration ranges or for patients with suspected interactions and unusual responses. A more structured protocol could schedule measurements at key stages of treatment, such as after a dose change or once a drug has reached steady state. That concept is essential: a blood sample taken too soon after treatment begins may not represent the drug’s stable exposure, while a sample collected at the wrong point in the dosing cycle can be difficult to interpret. Accurate TDM depends on timing, laboratory quality and clinical context.
The study’s central message is likely to be most useful when interpreted as part of a larger conversation about efficiency and individualized care, rather than as evidence that more tests automatically produce better outcomes. Hospital length of stay is a complex endpoint, and precision treatment must ultimately be judged by meaningful improvements in symptoms, safety, functioning and long-term relapse prevention. By examining the frequency of TDM alongside hospitalization duration, Hampf, Deckert, Walther and their colleagues highlight a measurable feature of modern psychiatric care that has often remained in the background. Their work could encourage future studies to determine when monitoring is most valuable, which patients benefit from it and whether laboratory-guided prescribing can make depression treatment more predictable without reducing care to numbers alone.
Subject of Research: Therapeutic drug monitoring in inpatient precision depression care and its relationship with the duration of hospitalization.
Article Title: Frequency of therapeutic drug monitoring in inpatient precision depression care and duration of hospitalization.
Article References: Hampf, C., Deckert, J., Walther, S. et al. “Frequency of therapeutic drug monitoring in inpatient precision depression care and duration of hospitalization.” Translational Psychiatry 16, 387 (2026). https://doi.org/10.1038/s41398-026-04316-8
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04316-8
Keywords: therapeutic drug monitoring, precision psychiatry, depression, inpatient care, antidepressants, pharmacokinetics, hospitalization duration, personalized medicine
